2min chapter

Breakpoints cover image

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

Breakpoints

CHAPTER

Long Acting Injectables for HIB

The second trial they talked about for treatment was more of a real world setting trial done in San Francisco and this was done in 51 patients in an urban public health HIB clinic. Patients there to be enrolled couldn't have had rope hivering mutations or more than one in a race inhibitor mutation. 24 patients at enrollment were already virologically suppressed and they remain suppressed and undetectable for the whole study period. 15 patients started with detectable by Remia which I think has been an area that people are unsure about with these long acting injectables. 12 of these patients got to an undetectable viral load. Two of those patients have never previously been suppressed ever in more than 10 years of

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode